APA

Buske C., Hoster E., Dreyling M., Eimermacher H., Wandt H., Metzner B., Fuchs R., Bittenbring J., Woermann B., Hohloch K., Hess G., Ludwig W., Schimke J., Schmitz S., Kneba M., Reiser M., Graeven U., Klapper W., Unterhalt M. & Hiddemann W. (20090206). The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). : Leukemia.

Chicago

Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, Fuchs R, Bittenbring J, Woermann B, Hohloch K, Hess G, Ludwig W-D, Schimke J, Schmitz S, Kneba M, Reiser M, Graeven U, Klapper W, Unterhalt M and Hiddemann W. 20090206. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). : Leukemia.

Harvard

Buske C., Hoster E., Dreyling M., Eimermacher H., Wandt H., Metzner B., Fuchs R., Bittenbring J., Woermann B., Hohloch K., Hess G., Ludwig W., Schimke J., Schmitz S., Kneba M., Reiser M., Graeven U., Klapper W., Unterhalt M. and Hiddemann W. (20090206). The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). : Leukemia.

MLA

Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, Fuchs R, Bittenbring J, Woermann B, Hohloch K, Hess G, Ludwig W-D, Schimke J, Schmitz S, Kneba M, Reiser M, Graeven U, Klapper W, Unterhalt M and Hiddemann W. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). : Leukemia. 20090206.